Actavis Said to Have Spurned $15 Billion Offer

May 14 (Bloomberg) -- Actavis rejected a cash-and-stock offer from fellow generic drugmaker Mylan for $15 billion, deciding instead to pursue talks to take over Warner Chilcott, said people familiar with the matter. Bloomberg's Jeff McCracken reports on Bloomberg Television's "Street Smart." (Source: Bloomberg)
No Deal for Greece Without Reforms: Vamvakidis
12:45 - Bank of America Merrill Lynch Managing Director and Head of European G10 FX Strategy Thanos Vamvakidis discusses the Greek debt crisis and its impact on the currency markets. He speaks to Bloomberg’s Mark Barton, Caroline Hyde and Manus Cranny on “Countdown.” (Source: Bloomberg)
  • Garner, Ahuja, Aziz, Holland, Naren on India's Modi
  • Nigerian Fuel Shortage Will Be Investigated: Oni
  • London's Ghost Tube Stations Get a New Life